HC Wainwright Increases Zymeworks (NASDAQ:ZYME) Price Target to $46.00

Zymeworks (NASDAQ:ZYME) had its price target raised by HC Wainwright from $32.00 to $46.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective suggests a potential upside of 91.03% from the stock’s current price.

Other research analysts have also issued research reports about the stock. Zacks Research lowered shares of Zymeworks from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 26th. B. Riley Financial reissued a “buy” rating and issued a $40.00 price target (up from $30.00) on shares of Zymeworks in a report on Friday, November 21st. Citizens Jmp set a $32.00 price objective on Zymeworks in a research report on Wednesday, December 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Zymeworks in a report on Wednesday, January 21st. Finally, Stifel Nicolaus increased their target price on Zymeworks from $40.00 to $47.00 and gave the stock a “buy” rating in a report on Tuesday, March 3rd. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Zymeworks has an average rating of “Moderate Buy” and a consensus target price of $37.10.

Zymeworks Stock Performance

Shares of Zymeworks stock opened at $24.08 on Friday. The company has a market cap of $1.78 billion, a P/E ratio of -22.30 and a beta of 1.23. The firm has a fifty day moving average of $23.72 and a two-hundred day moving average of $21.12. Zymeworks has a one year low of $9.03 and a one year high of $28.49.

Zymeworks (NASDAQ:ZYME) last released its earnings results on Monday, March 2nd. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.20). The firm had revenue of $2.52 million during the quarter, compared to analysts’ expectations of $21.78 million. Zymeworks had a negative net margin of 76.56% and a negative return on equity of 26.00%. Zymeworks’s revenue for the quarter was down 91.9% on a year-over-year basis. During the same quarter last year, the company posted ($0.31) earnings per share.

Insiders Place Their Bets

In other Zymeworks news, COO Mark Hollywood sold 6,120 shares of Zymeworks stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $22.67, for a total value of $138,740.40. Following the sale, the chief operating officer owned 132,913 shares of the company’s stock, valued at approximately $3,013,137.71. The trade was a 4.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Paul Andrew Moore sold 9,560 shares of the stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $22.67, for a total transaction of $216,725.20. Following the completion of the sale, the insider directly owned 48,497 shares in the company, valued at approximately $1,099,426.99. The trade was a 16.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 187,933 shares of company stock valued at $4,673,716. 33.51% of the stock is currently owned by company insiders.

Institutional Trading of Zymeworks

Several institutional investors and hedge funds have recently bought and sold shares of the stock. EcoR1 Capital LLC grew its position in Zymeworks by 33.1% during the 2nd quarter. EcoR1 Capital LLC now owns 22,970,388 shares of the company’s stock valued at $288,278,000 after purchasing an additional 5,710,840 shares during the last quarter. Rubric Capital Management LP grew its holdings in shares of Zymeworks by 22.1% in the fourth quarter. Rubric Capital Management LP now owns 5,750,000 shares of the company’s stock valued at $151,398,000 after purchasing an additional 1,039,449 shares in the last quarter. Perceptive Advisors LLC raised its stake in Zymeworks by 56.0% during the fourth quarter. Perceptive Advisors LLC now owns 3,261,850 shares of the company’s stock valued at $85,885,000 after purchasing an additional 1,171,187 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Zymeworks by 8.1% in the 4th quarter. Vanguard Group Inc. now owns 2,328,727 shares of the company’s stock worth $61,315,000 after buying an additional 174,293 shares in the last quarter. Finally, Vestal Point Capital LP increased its holdings in shares of Zymeworks by 53.5% in the 3rd quarter. Vestal Point Capital LP now owns 1,765,000 shares of the company’s stock worth $30,146,000 after buying an additional 615,000 shares during the last quarter. 92.89% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Zymeworks

Here are the key news stories impacting Zymeworks this week:

• Positive Sentiment: HC Wainwright raised its price target to $46 and reiterated a Buy rating — the new target implies substantial upside from current levels. Benzinga
• Positive Sentiment: Stifel Nicolaus boosted its price target to $47, another significant upward revision that supports a bullish view on ZYME’s longer‑term recovery. Stifel Target
• Positive Sentiment: Leerink Partners published a bullish forecast for Zymeworks, contributing to the cluster of upgrades and positive analyst sentiment this week. Leerink Report
• Neutral Sentiment: Lifesci Capital updated its FY-2026 and quarterly EPS forecasts with mixed changes: it materially improved the FY-2026 loss estimate (from -$1.40 to -$0.68) and sharply raised Q2/Q3 outlooks, but it lowered the Q1 estimate — a mixed signal that improves multi‑quarter visibility while acknowledging near‑term pressure. Lifesci Estimates
• Negative Sentiment: Recent quarterly results (reported March 2) showed a meaningful EPS miss and a ~92% YoY revenue decline, leaving Zymeworks unprofitable with negative margins — fundamentals that likely temper enthusiasm and explain part of the intraday weakness despite upgrades. Earnings Detail

Zymeworks Company Profile

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.